Diagnosis and classification of Vogt-Koyanagi-Harada disease

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 550-555

  Sakata, Viviane Mayumi ^a   Da Silva, Felipe Theodoro ^a   Hirata, Carlos Eduardo ^a   De Carvalho, Jozélio Freire ^b   Yamamoto, Joyce Hisae ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Alianca   (Brazil)

Author keywords

Autoimmune disease; Diffuse uveitis; Melanocyte; Vogt Koyanagi Harada disease

Indexed keywords

ADALIMUMAB; ANTIMETABOLITE; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; FLUOCINOLONE; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYDRIATIC AGENT; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

BRAZIL; CHOROID CAPILLARY LAYER; CHRONIC PATIENT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ECHOGRAPHY; ELECTRORETINOGRAM; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; GOLD STANDARD; HLA SYSTEM; HUMAN; HYPEREMIA; INDOCYANINE GREEN ANGIOGRAPHY; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PENETRATING TRAUMA; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINOGRAPHY; REVIEW; SCAR; TREATMENT OUTCOME; UVEA; VISION; VOGT KOYANAGI SYNDROME;

AUTOIMMUNE DISEASE; DIFFUSE UVEITIS; MELANOCYTE; VOGT-KOYANAGI-HARADA DISEASE;

ANGIOGRAPHY; DISEASE PROGRESSION; HLA-DRB1 CHAINS; HUMANS; TREATMENT OUTCOME; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 84896313996     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.023     Document Type: Review

References (65)

1. Moorthy R.S., Inomata H., Rao N.A. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995, 39:265-292.
2. Ohguro N., Sonoda K.-H., Takeuchi M., Matsumura M., Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol 2012, 56:432-435.
3. Chee S.P., Jap A., Bacsal C. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol 2009, 27:137-142.
4. Tugal-Tutkun I., Ozyazgan Y., Akova Y.A., et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey. Int Ophthalmol 2007, 27:117-123.
5. Snyder D.A., Tessler H.H. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980, 90:69-75.
6. Gouveia E.B., Yamamoto J.H., Abdalla M., et al. Causas das uveítes em serviço terciário em São Paulo, Brazil. Arq Bras Oftalmol 2004, 67:139-145.
7. Herbort C.P. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol 2007, 27:67-79.
8. a edição 2013-CBO 2013, Guanabara Kogan, Rio de Janeiro, [8570065752]. F. Oréfice (Ed.).
9. Read R.W., Holland G.N., Rao N.A., et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001, 131:647-652.
10. Beniz J., Forster D.J., Lean J.S., Smith R.E., Rao N.A. Variations in clinical features of Vogt-Koyanagi-Harada. Retina 1991, 11:275-280.
11. Da Silva F.T.B.G., Damico F.M., Marin M.L., et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories. Am J Ophthalmol 2009, 147:339-345.
12. Bouchenaki N., Herbort C.P. The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease. Ophthalmology 2001, 108:54-64.
13. Fardeau C., Chau Tran T.H., Gharbi B., Cassoux N., Bodaghi B., LeHoang P. Retinal fluorescein and indocyanine green angiography and optical coherence tomography in successive stages of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007, 27:163-172.
14. Forster D.J., Cano M.R., Green R.L., Rao N.A. Echographic features of the Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1990, 108:1421-1426.
15. Rao N.A., Gupta A., Dustin L., et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 2010, 117:591-599.
16. Wolfensberger T.J., Tufail A. Systemic disorders associated with detachment of the neurosensory retina and retinal pigment epithelium. Curr Opin Ophthalmol 2000, 11:455-461.
17. Greco A., Gallo A., Fusconi M., et al. Cogan's syndrome: an autoimmune inner ear disease. Autoimmun Rev 2013, 12:396-400.
18. Allegri P., Rissotto R., Herbort C.P., Murialdo U. CNS diseases and uveitis. J Ophthalmic Vis Res 2011, 6:284-308.
19. Rao N.A. Pathology of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007, 27:81-85.
20. Matsuda H., Sugiura S. Ultrastructural changes of the melanocyte in Vogt-Koyanagi-Harada syndrome and sympathetic ophthalmia. Jpn J Ophthalmol 1971, 15:69-80.
21. Yamaki K., Gocho K., Hayakawa K., Kondo I., Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000, 165:7323-7329.
22. Damico F.M., Bezerra F.T., Silva G.C., Gasparin F., Yamamoto J.H. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol 2009, 72:413-420.
23. Sugita S., Takase H., Kawaguchi T., Taguchi C., Mochizuki M. Crossreaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007, 27:87-95.
24. Tagawa Y., Sugiura S., Yakura H., Wakisaka A., Aizawa M. Letter: HLA and Vogt-Koyanagi-Harada syndrome. N Engl J Med 1976, 295:173.
25. Shindo Y., Inoko H., Yamamoto T., Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1* 0410. Br J Ophthalmol 1994, 75:223-226.
26. Davis J.L., Mittal K.K., Freidlin V., et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology 1990, 97:1137-1142.
27. Igniebi A., Gaafar A., Sheereen A., et al. HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis 2009, 15:1876-1880.
28. Arellanes-Garcia L., Bautista N., Mora P., Ortega-Larrocea G., Burguet A., Gorodezky C. HLA-DR is strongly associated with Vogt-Koyanagi-Harada disease in Mexican Mestizo patients. Ocul Immunol Inflamm 1998, 6:93-100.
29. Weisz J.M., Holland G.N., Roer L.N., et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology 1995, 102:1012-1015.
30. Goldberg A.C., Yamamoto J.H., Chiarella J.M., et al. HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease. Hum Immunol 1998, 59:183-188.
31. Maezawa N., Yano A. Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol Immunol 1984, 28:219-231.
32. Gocho K., Kondo I., Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2001, 42:2004-2009.
33. Sugita S., Takase H., Taguchi C., et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 2006, 47:2547-2554.
34. Damico F.M., Cunha-Neto E., Goldberg A.C., et al. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis. Invest Ophthalmol Vis Sci 2005, 46:2465-2471.
35. Chi W., Yang P., Li B., et al. Il-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007, 119:1218-1224.
36. Chen L., Yang P., Zhou H., et al. Diminished frequency and function of CD4+ CD25 high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci 2008, 49:3475-3482.
37. Yamaki K., Gocho K., Hayakawa K., Kondo I., Sukuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000, 165:7323-7329.
38. Suzuki S. Quantitative evaluation of "sunset glow" fundus in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1999, 43:327-333.
39. Jap A., Luu C.D., Yeo I., Chee S.P. Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease. Eye 2008, 22:240-245.
40. Miyanaga M., Kawaguchi T., Shimizu K., Miyata K., Mochizuki M. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007, 27:183-188.
41. Lai T.Y., Chan R.P., Chan C.K., Lam D.S. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye 2009, 23:543-548.
42. Yamanaka E., Ohguro N., Yamamoto S., Nakagawa Y., Imoto Y., Tano Y. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol 2002, 134:454-456.
43. Kawaguchi T., Horie S., Bouchenaki N., Ohno-Matsui K., Mochizuki M., Herbort C.P. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2010, 30:41-50.
44. Read R.W., Accorint M., Bodaghi B., et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2006, 142:119-124.
45. Chee S.P., Luu C.D., Cheng C.L., Lim W.K., Jap A. Visual function in Vogt-Koyanagi-Harada patients. Graefes Arch Clin Exp Ophthalmol 2005, 243:785-790.
46. Yang P., Fang W., Wang L., Wen F., Wu W., Kijstra A. Study of macular function by multifocal electroretinography in patients with Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2008, 146:767-771.
47. Da Silva F.T., Hirata C.E., Olivalves E., Oyamada M.K., Yamamoto J.H. Fundus-based and electroretinographic strategies for stratification of late-stage Vogt-Koyanagi-Harada disease patients. Am J Ophthalmol 2009, 148:939-945.
48. Keino H., Goto H., Usui M. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 2002, 240:878-882.
49. Herbort C.P., Mantovani A., Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease angiographic signs and utility in patient follow-up. Int Ophthalmol 2007, 27:173-182.
50. Ishihara K., Hangai M., Kita M., Yoshimura N. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography. Ophthalmology 2009, 116:1799-1807.
51. Da Silva F.T., Sakata V.M., Nakashima A., et al. Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophtahlmol 2013, 97:70-74.
52. Paredes I., Ahmed M., Foster C.S. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 2006, 14:87-90.
53. El-Asrar Am Abu, Al Tamimi M., Hemachandran S., Al-Mezaine H.S., Al-Muammar A., Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 2013, 91:e486-e493.
54. Kim E.C., Foster C.S. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006, 46:141-164.
55. Kaçmaz R.O., Kempen J.H., Newcom C., et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010, 117:576-584.
56. Liu X., Yang P., Lin X., et al. Inhibitory effect of cyclosporine A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol 2009, 131:333-342.
57. Abu El-Asrar A.M., Hemachandran S., Al-Mezaine H.S., Kangave D., Al-Muammar A.M. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012, 90:e603-e608.
58. Zmuda M., Tiev K.P., Knoeri J., Héron E. Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2013, 21:310-316.
59. Khalifa Y.M., Bailony M.R., Acharya N.R. Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm 2010, 18:218-222.
60. Andrade R.E., Muccioli C., Farah M.E., Nussenblatt R.B., Belfort R. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004, 137:572-574.
61. Khalifa Y., Loh A.R., Acharya N.R. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2009, 17:431-433.
62. Bykhovskaya I., Thorne J.E., Kempen J.H., Dunn J.P., Jabs D.A. Vogt-Koyanagi-Harada Disease: Clinical outcomes. Am J Ophthalmol 2005, 140:674-678.
63. Chee S.P., Jap A., Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol 2009, 147:154-161.
64. Read R.W., Rechodouni A., Butani N., et al. Complications and prognostic factors in Vogt-Koyanagi-Harada. Am J Ophthalmol 2001, 131:599-606.
65. Islam S.M., Numaga J., Matsuki K., Fujino Y., Maeda H., Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994, 35:752-756.